Anesthetic drugs & techniques

The effect of sugammadex on patient morbidity and quality of recovery after general anaesthesia: a systematic review and meta-analysis

Br J AnaesthPublished Systematic review and meta-analysis of randomised trials

Pooled result · PPCsResult — go to the resultOdds ratio 0.67 95% CI 0.47–0.95

Authors' conclusion

Although few trials reported on DAOH-30 or important patient outcomes, sugammadex is associated with a reduction in postoperative pulmonary complications, however, this might not translate to a difference in hospital length of stay, patient-reported quality of recovery, or mortality.

Study context

Population
Patients receiving NMBA reversal after GA, in randomised trials reporting important patient outcomes beyond the PACU43 articles
Participants
5,839 patients
Comparison
Sugammadex vs anticholinesterase-based or placebo reversal
Outcome
PPCs

Pooled result

As reported in the abstract

Odds ratio

0.67

95% CI 0.47–0.95

Sugammadex vs Control
OR 0.67 (95% CI 0.47–0.95)

Further pooled results

OutcomeSugammadexEstimate
DAOH-30 (sugammadex vs neostigmine-based reversal) · 30 daysOne trial25 (range 19–27) daysmedian difference 0.00 (CI −2.15 to 2.15)
Hospital LOS23 trialsmean difference −0.31 (CI −0.84 to 0.22)
OutcomeOR (CI)
PneumoniaEight trials0.51 (0.24–1.01)
Mortality11 trials · rarity of events precludes definitive conclusions0.39 (0.15–1.01)
  • DAOH-30 (sugammadex vs neostigmine-based reversal): Neostigmine 24 (range 21–27) days

DAOH-30 (sugammadex vs neostigmine-based reversal) · 30 days

Similar DAOH-30

Patient-reported quality of recovery

Similar with sugammadex vs control (11 trials, varied depending on metric used)

Original publication

The effect of sugammadex on patient morbidity and quality of recovery after general anaesthesia: a systematic review and meta-analysis. Br J Anaesth. Published 29 November 2023. doi:10.1016/j.bja.2023.10.032

Composed by AI from the published abstract and checked against it. How Briefs are made →

Get them every week

New studies on this topic in My Week and in your Monday e-mail.

We e-mail you a sign-in link and a code. No password, no spam.